A Clinical Study to Evaluate the Safety and Efficacy of the FloStent in Men With Benign Prostatic Hyperplasia Symptoms

NCT ID: NCT06849258

Last Updated: 2025-04-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

215 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-02-10

Study Completion Date

2032-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this study is to determine the safety and effectiveness of the FloStent, a medical device used to treat men with symptoms of Benign Prostatic Hyperplasia, compared to sham (procedure without deployment of the FloStent). All participants will undergo a flexible cystoscopy and those randomized to the treatment arm will receive the FloStent, while those randomized to the sham arm will not receive the FloStent.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Benign Prostatic Hyperplasia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Subjects will be randomized in a 2:1 (device:sham) ratio .
Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment - FloStent

Flexible cystoscopy procedure with FloStent implant deployed

Group Type EXPERIMENTAL

FloStent

Intervention Type DEVICE

Flexible cystoscopy to deploy medical device used to treat BPH

Sham Control

Flexible cystoscopy procedure without FloStent implant deployed

Group Type SHAM_COMPARATOR

Sham (Control)

Intervention Type DEVICE

Flexible Cystoscopy without deployment of medical device used to treat BPH

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

FloStent

Flexible cystoscopy to deploy medical device used to treat BPH

Intervention Type DEVICE

Sham (Control)

Flexible Cystoscopy without deployment of medical device used to treat BPH

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male subjects \> 45 years of age who have symptomatic BPH
* International Prostate Symptom Score (IPSS) score \>13
* Peak urinary flow rate (Qmax): \>5 mL/sec and \<13 mL/sec with minimum voided volume of \>125 mL
* Post-void residual (PVR) \<250 mL
* Prostate volume 25 to 80 mL
* Prostatic urethral length 20-50 mm
* Able to complete the study protocol and visits

Exclusion Criteria

* Presence of an artificial urinary sphincter or stent(s) in the urethra or prostate
* Prior minimally invasive intervention or surgical intervention of the prostate or urethra
* PSA \>10 ng/mL
* Bladder cancer or bladder stones
* Active urinary tract infection (UTI)
* Uncontrolled diabetes
* Part of a vulnerable population (cognitively challenged or are incarcerated)
Minimum Eligible Age

45 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Rivermark Medical

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Study Director, MD

Role: STUDY_DIRECTOR

Rivermark Medical, Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Michael G Oefelein Clinical Trials

Bakersfield, California, United States

Site Status RECRUITING

Comprehensive Urology Medical Group

Beverly Hills, California, United States

Site Status RECRUITING

Atlas Men's Health

La Mesa, California, United States

Site Status RECRUITING

Urology Group of Southern California

Los Angeles, California, United States

Site Status RECRUITING

Prestige Medical Group

Tustin, California, United States

Site Status RECRUITING

Urology Denver

Littleton, Colorado, United States

Site Status RECRUITING

Advanced Urology Institute

Daytona Beach, Florida, United States

Site Status RECRUITING

Duly Health

Lisle, Illinois, United States

Site Status RECRUITING

Loyola Medicine

Maywood, Illinois, United States

Site Status NOT_YET_RECRUITING

Southern Urology

Lafayette, Louisiana, United States

Site Status RECRUITING

Michigan Institute of Urology

Troy, Michigan, United States

Site Status RECRUITING

Sheldon Freedman Urology

Las Vegas, Nevada, United States

Site Status RECRUITING

Manhattan Medical Research NYU Langone

New York, New York, United States

Site Status RECRUITING

Northwell Health

Syosset, New York, United States

Site Status NOT_YET_RECRUITING

Associated Urologists of North Carolina

Raleigh, North Carolina, United States

Site Status RECRUITING

Conrad Pearson Clinic

Germantown, Tennessee, United States

Site Status RECRUITING

Midtown Urology Associates

Austin, Texas, United States

Site Status RECRUITING

Urology Austin/Urology America

Austin, Texas, United States

Site Status RECRUITING

Houston Methodist

Houston, Texas, United States

Site Status NOT_YET_RECRUITING

South Coast Urology

Wollongong, New South Wales, Australia

Site Status NOT_YET_RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States Australia

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Study Manager Study Director, MD

Role: CONTACT

414-758-7948

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

C0002 Rev. 07

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.